- Home
- ORKT vs NKGN Comparison
ORKT vs NKGN Comparison
Compare ORKT & NKGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKT
- NKGN
- Stock Information
- Founded
- ORKT 2003
- NKGN 2017
- Country
- ORKT Singapore
- NKGN United States
- Employees
- ORKT N/A
- NKGN N/A
- Industry
- ORKT
- NKGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ORKT
- NKGN Health Care
- Exchange
- ORKT NYSE
- NKGN Nasdaq
- Market Cap
- ORKT 34.7M
- NKGN 37.8M
- IPO Year
- ORKT 2024
- NKGN N/A
- Fundamental
- Price
- ORKT $1.10
- NKGN $0.57
- Analyst Decision
- ORKT Strong Buy
- NKGN
- Analyst Count
- ORKT 1
- NKGN 0
- Target Price
- ORKT $5.00
- NKGN N/A
- AVG Volume (30 Days)
- ORKT 5.4M
- NKGN 10.4M
- Earning Date
- ORKT 10-16-2024
- NKGN 02-25-2025
- Dividend Yield
- ORKT N/A
- NKGN N/A
- EPS Growth
- ORKT N/A
- NKGN N/A
- EPS
- ORKT N/A
- NKGN N/A
- Revenue
- ORKT $3,904,592.00
- NKGN N/A
- Revenue This Year
- ORKT N/A
- NKGN N/A
- Revenue Next Year
- ORKT N/A
- NKGN N/A
- P/E Ratio
- ORKT N/A
- NKGN N/A
- Revenue Growth
- ORKT N/A
- NKGN N/A
- 52 Week Low
- ORKT $0.62
- NKGN $0.20
- 52 Week High
- ORKT $8.00
- NKGN $4.06
- Technical
- Relative Strength Index (RSI)
- ORKT N/A
- NKGN 52.48
- Support Level
- ORKT N/A
- NKGN $0.40
- Resistance Level
- ORKT N/A
- NKGN $0.91
- Average True Range (ATR)
- ORKT 0.00
- NKGN 0.13
- MACD
- ORKT 0.00
- NKGN 0.00
- Stochastic Oscillator
- ORKT 0.00
- NKGN 40.78
About ORKT ORANGEKLOUD TECHNOLOGY INC
Orangekloud Technology Inc is a company that operates through its subsidiaries provide IT consultancy services and distribution of related products and services. The Company also offers ERPs predominately in Singapore. It derives revenue from platform subscriptions, license and products and professional services.
About NKGN NKGen Biotech Inc.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.